The Food and Drug Administration United States on Saturday authorized Johnson & Johnson's COVID-19 vaccine for emergency use. The vaccine is the third to be approved for use in the United States, and the first that requires only one shot.
The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend authorizing the vaccine by Janssen, a division of Johnson & Johnson, on Friday. The committee provides expert advice to the FDA but does not have final say on approval.
The FDA granted emergency use authorizations for the Pfizer and Moderna coronavirus vaccines in December, with vaccinations beginning just days later. Those vaccines are said to be 95% and 94% effective, respectively. Unlike the Pfizer and Moderna vaccines, Johnson & Johnson's, also known as the Janssen COVID-19 Vaccine, requires only a single shot
The Johnson & Johnson vaccine has also shown 85 percent efficacy
against severe forms of COVID-19 and 100 percent efficacy against
hospitalization and death,
Johnson & Johnson has said it will provide the US with 100 million doses by the end of June, the Times reported, adding that the vaccine could start reaching Americans by early next week.
In early February, a week after announcing that its single-dose vaccine was 66% effective overall in preventing COVID-19 in a global clinical trial, Johnson & Johnson submitted an application requesting the FDA grant the emergency use authorization.










